Endocrine Disorders in Childhood Brain Tumour Survivors: A Single-Centre Study

Nurul Wahidah Ramezan; Suhaimi Hussain; Norsarwany Mohamad; Najib Majdi Yaacob

doi:10.15605/jafes.039.01.05

Authors

Nurul Wahidah Ramezan Universiti Sains Malaysia Hospital https://orcid.org/0009-0001-1979-4416
Suhaimi Hussain Universiti Sains Malaysia Hospital https://orcid.org/0000-0002-7164-3076
Norsarwany Mohamad Universiti Sains Malaysia Hospital
Najib Majdi Yaacob School of Medical Science https://orcid.org/0000-0002-6860-1430

DOI:

https://doi.org/10.15605/jafes.039.01.05

Keywords:

Endocrine disorder, Childhood Brain Tumor Survivors, Risk Factors.

Abstract

Objective: The study aims to determine the prevalence and risk factors for endocrine disorders in childhood brain tumour survivors.

Methodology: 124 childhood brain tumour survivors aged 18 years old or younger with either stable disease or in remission, and had survived for at least 2 years after diagnosis were included in the study. Demographic data (age at diagnosis, gender, ethnicity, socioeconomic status), clinical clues for endocrine disorders, anthropometrics (weight, height, midparental height), pubertal staging, tumour-related characteristics, treatment modalities and endocrine laboratory measurements at diagnosis and during follow up were obtained. Logistic regression was applied to evaluate risk factors for endocrine disorders in childhood brain tumour survivors.

Results: The prevalence of endocrine disorders in childhood brain tumour survivors was 62.1%. The risk factors were high BMI [adjusted odds ratio (OR) 1.29, 95% CI: 1.12 to 1.5], high-risk site [adjusted odds ratio (OR) 7.15, 95% CI: 1.41 to 36.3] and chemotherapy [adjusted odds ratio (OR) 0.18 , 95% CI: 0.05 to 0.62].

Conclusion: The prevalence of endocrine disorders in childhood brain tumour survivors in our centre was 62.1%. The significant risk factors were high BMI, tumour location (suprasellar and intrasellar) and chemotherapy.

Downloads

Download data is not yet available.

Author Biographies

Nurul Wahidah Ramezan, Universiti Sains Malaysia Hospital

Department of Pediatrics

Suhaimi Hussain, Universiti Sains Malaysia Hospital

Department of Pediatrics

Norsarwany Mohamad, Universiti Sains Malaysia Hospital

Department of Pediatrics

Najib Majdi Yaacob, School of Medical Science

Department of Biostatistics and Research Methodology

References

Nandagopal R, Laverdière C, Mulrooney D, Hudson MM, Meacham L. Endocrine late effects of childhood cancer therapy: A report from the children’s oncology group. Horm Res. 2008;69(2):65-74. https://pubmed.ncbi.nlm.nih.gov/18059086. https://doi.org/10.1159/000111809.

Ostrom QT, De Blank PM, Kruchko C, et al. Alex’s Lemonade Stand Foundation infant and childhood primary brain and central nervous system tumour diagnosed in the United States in 2007-2011. Neuro Oncol. 2015;16(Suppl 10):x1-36. https://pubmed.ncbi.nlm.nih.gov/25542864. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4277295. https://doi.org/10.1093/neuonc/nou327.

Azizah AM, Nor Saleha IT, Noor Hashimah A, Asmah Za, Mastulu W. Malaysia National Cancer Registry Report 2007-2011; 2015.

Takada A, Ii N, HIrayama M, et al. Long-term follow-up of intensive chemotherapy followed by reduced-dose and reduced-field irradiation for intracranial germ cell tumor. J Neurosurg Pediatr. 2018;23(3):317-24. https://pubmed.ncbi.nlm.nih.gov/30497152. https://doi.org/10.3171/2018.9.PEDS18181.

Chemaitilly W, Cohen LE, Mostoufi-Moab S, et al. Endocrine late effects in childhood cancer survivors. J Clin Oncol. 2018;36(21):2153-9. https://pubmed.ncbi.nlm.nih.gov/29874130. https://doi.org/10.1200/JCO.2017.76.3268.

Merchant TE, Conklin HM, Wu S, Lustig RH, Xiong X. Late effects of conformal radiation therapy for pediatric patients with low-grade glioma: Prospective evaluation of cognitive, endocrine, and hearing deficits. J Clin Oncol. 2009;27(22):3691-7. https://pubmed.ncbi.nlm.nih.gov/19581535. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2799064. https://doi.org/10.1200/JCO.2008.21.2738.

Chemaitilly W, Li Z, Huang S, et al. Anterior hypopituitarism in adult survivors of childhood cancers treated with cranial radiotherapy: A report from St Jude Lifetime Cohort. J Clin Oncol. 2015;33(5):492-500. https://pubmed.ncbi.nlm.nih.gov/25559807. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4314596. https:///doi.org/10.1200/JCO.2014.56.7933.

Ng YJ, Jalaludin MY, Foo JC, Qaddoumi I, Rajagopal R. Prevalence and risk factors for endocrine disorders in childhood brain tumors From a single tertiary center in Malaysia. J Pediatr Hematol Oncol. 2022;44(4):159-66. https://pubmed.ncbi.nlm.nih.gov/35446802. https://doi.org/10.1097/MPH.0000000000002447.

Clement SC, Schouten-van Meeteren AYN, Kremer LCM, van Trotsenburg ASP, Caron HN, van Santen HM. High prevalence of early hypothalamic-pituitary damage in childhood brain tumor survivors: Need for standardized follow-up programs. Pediatr Blood Cancer. 2014;61(12):2285-9. https://pubmed.ncbi.nlm.nih.gov/25131941. https://doi.org/10.1002/pbc.25176.

Heo J, Lee HS, Hwang JS, Noh OK, Kim L, Park JE. Prevalence of endocrine disorders in childhood brain tumor survivors in South Korea. In Vivo. 2019;33(6):2287-91. https://pubmed.ncbi.nlm.nih.gov/31662569. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6899123. https://doi.org/10.21873/invivo.11735.

Clement, S. C. et al. Prevalence and risk factors of early endocrine disorders in childhood brain tumor survivors: A nationwide, multicenter study. J Clin Oncol. 216;34(36):4362-70. https://pubmed.ncbi.nlm.nih.gov/27998218. https://doi.org/10.1200/JCO.2016.67.5025.

Shaw S. Endocrine late effects in survivors of pediatric brain tumors. J Pediatr Oncol Nurs. 2009;26(5):295-302. https://pubmed.ncbi.nlm.nih.gov/19837959. https://doi.org/10.1177/1043454209343180.

Cohen LE, Gordon JH, Popovsky EY, et al. Late effects in children treated with intensive multimodal therapy for high-risk neuroblastoma: High incidence of endocrine and growth problems. Bone Marrow Transplant. 2014;49(4):502-8. https://pubmed.ncbi.nlm.nih.gov/24442245. https://doi.org/10.1038/bmt.2013.218.

Patterson BC0, Wasilewski-Masker K, Ryerson AB0, Mertens A, Meacham L. Endocrine health problems detected in 519 patients evaluated in a pediatric cancer survivor program. J Clin Endocrinol Metab. 2012;97(3):810-8. https://pubmed.ncbi.nlm.nih.gov/22188743. https://doi.org/10.1210/jc.2011-2104.

Oberfield SE, Allen JC, Pollack J, New MI, Levine LS. Long-term endocrine sequelae after treatment of medulloblastoma. Prospective study of growth and thyroid function. J Paediatr. 1986;108(2):219-23. https://pubmed.ncbi.nlm.nih.gov/3944706. https://doi.org/10.1016/s0022-3476(86)80986-6.

Fang FY, Rosenblum JS, Ho WS, Heiss JD. New developments in the pathogenesis, therapeutic targeting, and treatment of pediatric medulloblastoma. Cancers (Basel). 2022;14(9):2285. https://pubmed.ncbi.nlm.nih.gov/35565414. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9100249. https://doi.org/10.3390/cancers14092285.

Maciel J, Dias D, Cavaco D, Donato s, Pereira MC, Simões-Pereira MC. Growth hormone deficiency and other endocrinopathies after childhood brain tumors: Results from a close follow-up in a cohort of 242 patients. J Endocrinol Invest.2021;44(11):2367-74. https://pubmed.ncbi.nlm.nih.gov/33683662. https://doi.org/10.1007/s40618-021-01541-4.

Lone DW, Sadak KT, Miller BS, et al. Prevalence of childhood growth hormone deficiency in survivors of pediatric intracranial germ cell tumors. J Clin Oncol. 2022;12(3):79-88. https://pubmed.ncbi.nlm.nih.gov/36249955. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9555288. https://doi.org/10.14740/jem807.

Lawson SA, Home VE, Golekoh MC, et al. Hypothalamic–pituitary function following childhood brain tumors: Analysis of prospective annual endocrine screening. Pediatr Blood Cancer. 2019;66(5):e27631.

Gurney JG, Ness KK, Stovall M, et al. Final height and body mass index among adult survivors of childhood brain cancer: Childhood cancer survivor study. J Clin Endocrinol Metab. 2003;88(10):4731-9. https://pubmed.ncbi.nlm.nih.gov/14557448. https://doi.org/10.1210/jc.2003-030784.

Pasqualini T, Diez B, Domene H, et al. Long-term endocrine sequelae after surgery, radiotherapy and chemotherapy in children with medulloblastoma. Cancer. 1987;59(4):801-6. https://pubmed.ncbi.nlm.nih.gov/3802038. https://doi.org/10.1002/1097-0142(19870215)59:4<801::aid-cncr2820590424>3.0.co;2-z.

Nyanti L, Samsudin A, Tiong IK. Syndrome of inappropriate antidiuretic hormone secretion and Leser-Trélat syndrome as uncommon paraneoplastic manifestations of renal malignancy - A geriatric experience: A case report. J Med Case Rep. 2019;13(1):188. https://pubmed.ncbi.nlm.nih.gov/31221202. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587240. https://doi.org/10.1186/s13256-019-2122-8.

Kumar MM, Foster JR, Sharan S, DeRibaupierre S, McKillop SJ, Kornecki A. Transient blindness as the primary symptom of acute hyponatremia post surgery. J Pediatr Intensive Care. 2013;1(3):169-72. https://pubmed.ncbi.nlm.nih.gov/31214404. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6530693. https://doi.org/10.3233/PIC-2012-028.

Das UN. Obesity: Genes, brain, gut, and environment. Nutrition. 2010;26(5):459-73. https://pubmed.ncbi.nlm.nih.gov/20022465. https://doi.org/10.1016/j.nut.2009.09.020.

Mediavilla C. Bidirectional gut-brain communication: A role for orexin-A. Neurochem Int. 2020;141:104882. https://pubmed.ncbi.nlm.nih.gov/33068686. https://doi.org/10.1016/j.neuint.2020.104882.

Lutsig RH, Post SR, Merchant T. Risk factors for the development of obesity in children surviving brain tumour. J Clin Endocrinol Metab. 2003;88(2):611-6. https://pubmed.ncbi.nlm.nih.gov/12574189. https://doi.org/10.1210/jc.2002-021180.

Cooksey R, Wu SY, Bowers D, et al. Metabolic syndrome is a sequalae of radiation exposure in hypothalamic obesity among survivors of childhood brain tumours. J Investig Med. 2019;67(2):295-302. https://pubmed.ncbi.nlm.nih.gov/30530528. https://doi.org/10.1136/jim-2018-000911.

Yalçin B, Kremer LCM, van Dalen EC. High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma. Cochrane Database Syst Rev.2015;2015(10):CD006301. https://pubmed.ncbi.nlm.nih.gov/26436598. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8783746. https://doi.org/10.1002/14651858.CD006301.pub4.

Khanal N, Ahmed SS, Kalra M, et al. The effects of hypogonadism on quality of life in survivors of germ cell tumors treated with surgery alone versus surgery plus platinum-based chemotherapy. Support Care Cancer. 2020;28(7):3165-70. https://pubmed.ncbi.nlm.nih.gov/31707501. https://doi.org/10.1007/s00520-019-05117-0.

Zaid MA, Dinh PC, Monahan PO, et al. Adverse health outcomes in relationship to hypogonadism after chemotherapy: A multicenter study of testicular cancer survivors. J Natl Compr Canc Netw. 2019;17(5):459-68. https://pubmed.ncbi.nlm.nih.gov/31085753. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6712564. https://doi.org/10.6004/jnccn.2018.7109.